지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2013.1
- 수록면
- 28 - 33 (6page)
이용수
초록· 키워드
오류제보하기
Background: The primary purpose of this study was to investigate the prevalence and characteristics of p16 methylation and determine the prognostic implications of the clinical data, hematologic data, and p16 methylation changes in plasma cell myeloma (PCM). Methods: We reviewed clinical characteristics and results of laboratory tests and investigated the response to combination chemotherapy and survival time. DNA methylation of the p16 gene was tested by methylation-specific PCR. Clinical significance was evaluated. Results: A total of 103 patients were enrolled in this study. The median patient age was 59.0 yr at diagnosis and the male to female ratio was 1.15:1. According to the International Staging System (ISS), patients were diagnosed as stage: I (N=17, 16.5%), II (N=41, 39.8%), III (N=39, 37.9%), or not classified (N=6). Forty-five (43.7%) patients and 36 (35.0%) patients showed abnormal karyotype and complex karyotype, respectively, on the chromosome study. The p16 methylation was observed in 39 (37.9%) of 103 patients, but there was no significant association between p16 methylation status and other clinical or laboratory factors and survival outcome. Male gender, albumin, and complex karyotype were independent prognostic factors for overall survival according to multivariate analysis (P <0.05). Conclusions: The male gender, low serum albumin level, and complex karyotype were independent poor prognostic factors for PCM. p16 methylation was relatively common in PCM,but did not influence the survival outcome.
목차
등록된 정보가 없습니다.
참고문헌 (27)
참고문헌 신청
Hari PN / 2009 / Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant / Leukemia 23:1528~1534
Harousseau JL / 2008 / Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up / Ann Oncol 19(S2):255~257
Avet-Loiseau H / 2007 / Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome / Blood 109 : 3489 ~ 3495
Blade J / 2008 / Prognostic factors for multiple myeloma in the era of novel agents / Ann Oncol 19 (S7) : 7117 ~ 7120
Brenner H / 2009 / Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010 / Haematologica 94 : 270 ~ 275
Harousseau JL / 2008 / Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up / Ann Oncol 19(S2):255~257
Avet-Loiseau H / 2007 / Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome / Blood 109 : 3489 ~ 3495
Blade J / 2008 / Prognostic factors for multiple myeloma in the era of novel agents / Ann Oncol 19 (S7) : 7117 ~ 7120
Brenner H / 2009 / Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010 / Haematologica 94 : 270 ~ 275
이 논문의 저자 정보
최근 본 자료
댓글(0)
0